Fielmann AG (FIE) Receives Average Rating of “Hold” from Analysts

Share on StockTwits

Shares of Fielmann AG (FRA:FIE) have received an average recommendation of “Hold” from the thirteen research firms that are covering the company, Marketbeat reports. Two equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and three have assigned a buy rating to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is €59.96 ($69.72).

A number of equities analysts recently weighed in on the company. Commerzbank set a €60.00 ($69.77) price target on Fielmann and gave the company a “neutral” rating in a research report on Friday, November 9th. DZ Bank reiterated a “neutral” rating on shares of Fielmann in a research report on Thursday, September 27th. Hauck & Aufhaeuser set a €44.00 ($51.16) price target on Fielmann and gave the company a “sell” rating in a research report on Monday, September 24th. Independent Research set a €61.00 ($70.93) price target on Fielmann and gave the company a “neutral” rating in a research report on Friday, November 2nd. Finally, Baader Bank set a €66.00 ($76.74) price target on Fielmann and gave the company a “buy” rating in a research report on Thursday, November 1st.

Shares of FRA:FIE traded up €0.60 ($0.70) during midday trading on Friday, reaching €56.40 ($65.58). The company had a trading volume of 42,366 shares. Fielmann has a 1-year low of €65.50 ($76.16) and a 1-year high of €77.50 ($90.12).

Fielmann Company Profile

Fielmann Aktiengesellschaft invests in and operates optical and hearing aid businesses in Germany, Switzerland, Austria, and internationally. The company designs, manufactures, distributes, and retails visual aids and other optical products, including glasses, frames, lenses, sunglasses, contact lenses, and related articles and accessories, as well as hearing aids and accessories.

See Also: What is the S&P 500 Index?

Analyst Recommendations for Fielmann (FRA:FIE)

Receive News & Ratings for Fielmann Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fielmann and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2019 BBNS.